ViiV Healthcare announced data from the phase I CLARITY open-label, crossover study, showing clinically relevant differences in injection site reaction (ISR) acceptability and tolerability, with 69% of HIV-negative adults finding cabotegravir long-acting (CAB LA) injections to be “totally or very acceptable” vs 48% for lenacapavir (LEN) injections. Data presented at EACS 2025 also showed 90% of HIV-negative adults and 86% of healthcare providers preferred CAB LA injections over LEN injections after a single dose, and ISR events were more frequent and visible with LEN than with CAB LA.
Read the full company press release here.